Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation

Bibliography

• Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. Drugs 2008;68(2):209-29
   PubMed Web of Science ®Google Scholar
• Gacci M, Eardley I, Giuliano F, Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60(4):809-25
   PubMed Web of Science ®Google Scholar
• Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003;15(4):299-306
   PubMed Web of Science ®Google Scholar
• Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011;8(6):1747-53
   PubMed Web of Science ®Google Scholar
• Wessells HRoy J, Bannow J, Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61(3):579-84
   PubMed Web of Science ®Google Scholar
• Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007;52(1):54-70
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Stein U, Aumuller G, Remberger K, Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29(4):261-7
   PubMed Web of Science ®Google Scholar
• George FW, Johnson L, Wilson JD. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. Endocrinology 1989;125(5):2434-8
   PubMed Web of Science ®Google Scholar
• Imperato-McGinley J, Gautier T, Zirinsky K, Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1992;75(4):1022-6
   PubMed Web of Science ®Google Scholar
• Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61(4 Suppl 1):2-7
   PubMed Web of Science ®Google Scholar
• Kaufman M, Pinsky L. The dissociation of testosterone- and 5 alpha-dihydrotestosterone-receptor complexes formed within cultured human genital skin fibroblasts. J Steroid Biochem 1983;18(2):121-5
   PubMedGoogle Scholar
• Schirar A, Bonnefond C, Meusnier C, Devinoy E, Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology 1997;138(8):3093-102
   PubMed Web of Science ®Google Scholar
• Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005;2(6):759-70
   PubMed Web of Science ®Google Scholar
• Traish AM. Androgens play a pivotal role in maintaining penile tissue architecture and erection: a review. J Androl 2009;30(4):363-9
   PubMed Web of Science ®Google Scholar
• Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006;8(1):3-9
   PubMed Web of Science ®Google Scholar
• Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med 2008;5(12):2917-24
   PubMed Web of Science ®Google Scholar
• Kiyokage E, Toida K, Suzuki-Yamamoto T, Ishimura K Localization of 5alpha-reductase in the rat main olfactory bulb. J Comp Neurol 2005;493(3):381-95
   PubMed Web of Science ®Google Scholar
• Lephart ED. Age-related changes in brain and pituitary 5 alpha-reductase with finasteride (Proscar) treatment. Neurobiol Aging 1995;16(4):647-50
   PubMed Web of Science ®Google Scholar
• Iehle C, Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68(5-6):189-95
   PubMed Web of Science ®Google Scholar
• Uemura M, Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99(1):81-6
   PubMed Web of Science ®Google Scholar
• Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 1990;87(10):3640-4
   PubMed Web of Science ®Google Scholar
• Labrie F, Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131(3):1571-3
   PubMed Web of Science ®Google Scholar
• Normington K, Russell DW. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 1992;267(27):19548-54
   PubMed Web of Science ®Google Scholar
• Thigpen AE, Silver RI, Guileyardo JM, Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92(2):903-10
   PubMed Web of Science ®Google Scholar
• Iehle C, Delos S, Guirou O, Human prostatic steroid 5 alpha-reductase isoforms–a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54(5-6):273-9
   PubMed Web of Science ®Google Scholar
• Thomas LN, Lazier CB, Gupta R, Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63(3):231-9
   PubMed Web of Science ®Google Scholar
• Godoy A, Kawinski E, Li Y, 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 2011;71(10):1033-46
   PubMed Web of Science ®Google Scholar
• Kramer BS, Hagerty KL, Justman S, Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: american Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009;27(9):1502-16
   PubMed Web of Science ®Google Scholar
• Theoret MR, Ning YM, Zhang JJ, The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365(2):97-9
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44(1):82-8
   PubMed Web of Science ®Google Scholar
• Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97(Suppl 2):34-8; discussion 44-5
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338(9):557-63
   PubMed Web of Science ®Google Scholar
• Carlin JR, Hoglund P, Eriksson LO, Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 1992;20(2):148-55
   PubMed Web of Science ®Google Scholar
• Tacklind J, Fink HA, Macdonald R, Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010(10):CD006015
   PubMed Web of Science ®Google Scholar
• Clark RV, Hermann DJ, Cunningham GR Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-84
   PubMed Web of Science ®Google Scholar
• Imperato-McGinley J, Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186(4170):1213-15
   PubMed Web of Science ®Google Scholar
• Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 1995;27(4):267-73
   PubMed Web of Science ®Google Scholar
• Kaufman KD, Olsen EA, Whiting D, Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39(4 Pt 1):578-89
   PubMed Web of Science ®Google Scholar
• Leyden J, Dunlap F, Miller B Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40(6 Pt 1):930-7
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs 1999;57(1):111-26
   PubMed Web of Science ®Google Scholar
• Lowe FC, McConnell JD, Hudson PB, Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003;61(4):791-6
   PubMed Web of Science ®Google Scholar
• Mondaini N, Gontero P, Giubilei G, Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007;4(6):1708-12
   PubMed Web of Science ®Google Scholar
• Olsen EA, Hordinsky M, Whiting D, The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55(6):1014-23
   PubMed Web of Science ®Google Scholar
• Byrnes CA, Morton AS, Liss CL, Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin Ther 1995;17(5):956-69
   PubMed Web of Science ®Google Scholar
• Nickel JC, Fradet Y, Boake RC, Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155(9):1251-9
   PubMed Web of Science ®Google Scholar
• Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag 2009;5(3):535-45
   PubMedGoogle Scholar
• Castro-Magana M, Angulo M, Fuentes B, Effect of finasteride on human testicular steroidogenesis. J Androl 1996;17(5):516-21
   PubMed Web of Science ®Google Scholar
• Frink M, Hsieh YC, Hu S, Mechanism of salutary effects of finasteride on post-traumatic immune/inflammatory response: upregulation of estradiol synthesis. Ann Surg 2007;246(5):836-43
   PubMed Web of Science ®Google Scholar
• Duborija-Kovacevic N, Jakovljevic V, Sabo A, Tomic Z, Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals. Eur J Drug Metab Pharmacokinet 2008;33(3):181-6
   PubMed Web of Science ®Google Scholar
• Romer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms. J Cosmet Dermatol 2010;9(4):331-2
   PubMedGoogle Scholar
• Duskova M, Hill M, Hanus M, Finasteride treatment and neuroactive steroid formation. Prague Med Rep 2009;110(3):222-30
   PubMedGoogle Scholar
• Aggarwal S, Thareja S, Verma A, An overview on 5alpha-reductase inhibitors. Steroids 2010;75(2):109-53
   PubMed Web of Science ®Google Scholar
• O'Leary MP, Roehrborn C, Andriole G, Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92(3):262-6
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin Jvan Erps P, Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46(4):488-94; discussion 495
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41
   PubMed Web of Science ®Google Scholar
• Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol 2005;7(4):203-10
   PubMedGoogle Scholar
• Marberger M, Roehrborn CG, Marks LS, Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91(4):1323-8
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362(13):1192-202
   PubMed Web of Science ®Google Scholar
• Whiting DA, Olsen EA, Savin R, Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003;13(2):150-60
   PubMed Web of Science ®Google Scholar
• Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51(5):677-86
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
   PubMed Web of Science ®Google Scholar
• Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136(4):1495-501
   PubMed Web of Science ®Google Scholar
• Bradshaw WG, Baum MJ, Awh CC. Attenuation by a 5 alpha-reductase inhibitor of the activational effect of testosterone propionate on penile erections in castrated male rats. Endocrinology 1981;109(4):1047-51
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Gur S, Tracey AJ, The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011;8(11):3066-74
   PubMed Web of Science ®Google Scholar
• Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med 2011;8(7):1829-31
   PubMed Web of Science ®Google Scholar
• Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007;19(4):386-92
   PubMed Web of Science ®Google Scholar
• Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29(1):17-25
   PubMed Web of Science ®Google Scholar
• Lepor H, Williford WO, Barry MJ, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335(8):533-9
   PubMed Web of Science ®Google Scholar
• Kirby RS, Roehrborn C, Boyle P, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61(1):119-26
   PubMed Web of Science ®Google Scholar
• Hudson PB, Boake R, Trachtenberg J, Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999;53(4):690-5
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol 2002;167(2 Pt 2):1102-7; discussion 08
   PubMed Web of Science ®Google Scholar